Wednesday, April 4, 2007
Sangart Scores $50M
San Diego-based Sangart, a biopharmaceutical company focused on research, development and commercialization of oxygen transport agents, said today it has raised $50M in a Series F financing. The round was led by Leucadia National Corporation, and also included warrants that if exercised could provide an additional $50M in future funding. According to Sangart, this round brings the company's total raise to more than $120M. Sangart's products are focused on the area of alternatives to blood transfusions. More information »
Support Our Coverage Of SoCal's Tech Ecosystem!
Tap into Southern California's growing tech ecosystem, by signing up for a two week free trial membership. Find new tech customers, find high tech startups and jobs, find venture funding, help support our news coverage!Learn More